Innovations in cancer diagnostics
bioTheranostics discovers, develops, and commercializes molecular-based diagnostic, prognostic, and predictive tests that support physicians in the treatment of patients with cancer.
Molecular cancer classification that aids in determining the tumor of origin
CancerTYPE ID® is a standardized, objective molecular test based on the differential expression of 92 genes that classifies tumors by matching the gene expression pattern of a patient’s tumor tissue to a database of known tumor types and histological subtypes.1-3
Molecular insights for breast cancer risk prognosis
Breast Cancer IndexSM (BCI) predicts breast cancer recurrence risk in patients with ER+, LN- breast cancer.4
Actionable biomarker information for therapeutic decision making
PRÉCIS® Precision Medicine by bioTheranostics biomarker profiles for non-small cell lung and colorectal cancer detect clinically relevant tumor biomarkers.
References:
1.) Ma, et al. Molecular Classification of Human Cancers Using a 92-Gene Real Time Quantitative Polymerase Chain Reaction Assay. Archives of Pathology and Laboratory Medicine, 130: 465-473, 2006. 2.) Erlander et al. Performance and Clinical Evaluation of the 92-Gene Real-Time PCR Assay for Tumor Classification. J Mol Diag. 2011 Sept; 13(5): 493-502. 3.) Kerr SE et al. Multisite Validation Study To Determine Performance Characteristics of a 92-gene Molecular Cancer Classifier. Clin Cancer Res. 2012 May 30. 4.) Jerevall P, et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer. 2011 May 24;104(11):1762-9.
Client Services (877) 886-6739
